Reply: Potential role of Janus kinase inhibitors in COVID-19 - 18/05/20
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Funding sources: None. |
|
Conflicts of interest: Dr Napolitano has acted as a speaker for Sanofi. Dr Fabbrocini has acted as a speaker and consultant for AbbVie and LEO Pharma. Dr Patruno has acted as a speaker and consultant for AbbVie, Novartis, Pfizer, and Sanofi. |
|
IRB approval status: Not applicable. |
|
Reprints not available from the authors. |
Bienvenue sur EM-consulte, la référence des professionnels de santé.